Clinical Focus ›› 2023, Vol. 38 ›› Issue (10): 898-903.doi: 10.3969/j.issn.1004-583X.2023.10.006
Previous Articles Next Articles
Liu Ye1, Ruan Guiren1, Liu Xiaoqing1, Shi Xiaochun1(), Fei Guijun2
Received:
2023-05-31
Online:
2023-10-20
Published:
2024-01-03
Contact:
Shi Xiaochun
E-mail:shixch7722@163.com
CLC Number:
Liu Ye, Ruan Guiren, Liu Xiaoqing, Shi Xiaochun, Fei Guijun. Diagnosis and differential diagnosis of pancreatic tuberculosis[J]. Clinical Focus, 2023, 38(10): 898-903.
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.10.006
项目 | PTB (n=23) | PMT (n=23) | 统计值 | P值 |
---|---|---|---|---|
年龄(岁) | 49±13 | 55±9 | t=-1.797 | 0.079 |
性别[男,例(%)] | 15(65.2) | 15(65.2) | χ2=0 | 1 |
糖尿病[例(%)] | 1(4.4) | 5(21.7) | χ2=1.725 | 0.189 |
肺结核暴露史[例(%)] | 3(13.0) | 0(0.0) | 0.233* | |
既往结核病史[例(%)] | 4(17.4) | 0(0.0) | 0.109* | |
吸烟[例(%)] | 6(26.1) | 10(43.5) | χ2=1.533 | 0.216 |
饮酒[例(%)] | 4(17.4) | 7(30.4) | χ2=1.075 | 0.300 |
恶性肿瘤家族史[例(%)] | 5(21.7) | 6(26.1) | χ2=0.119 | 0.730 |
腹痛[例(%)] | 12(52.2) | 12(52.2) | χ2=0 | 1 |
发热[例(%)] | 5(21.7) | 2(8.7) | χ2=0.674 | 0.412 |
黄疸[例(%)] | 2(8.7) | 3(13.0) | χ2=0 | 1 |
腹部包块[例(%)] | 1(4.4) | 0(0.0) | 1* | |
体重下降[例(%)] | 8(34.8) | 8(34.8) | χ2=0 | 1 |
纳差[例(%)] | 3(13.0) | 3(13.0) | χ2=0 | 1 |
乏力[例(%)] | 2(8.7) | 3(13.0) | χ2=0 | 1 |
Tab. 1 Comparison of clinical characteristics between groups
项目 | PTB (n=23) | PMT (n=23) | 统计值 | P值 |
---|---|---|---|---|
年龄(岁) | 49±13 | 55±9 | t=-1.797 | 0.079 |
性别[男,例(%)] | 15(65.2) | 15(65.2) | χ2=0 | 1 |
糖尿病[例(%)] | 1(4.4) | 5(21.7) | χ2=1.725 | 0.189 |
肺结核暴露史[例(%)] | 3(13.0) | 0(0.0) | 0.233* | |
既往结核病史[例(%)] | 4(17.4) | 0(0.0) | 0.109* | |
吸烟[例(%)] | 6(26.1) | 10(43.5) | χ2=1.533 | 0.216 |
饮酒[例(%)] | 4(17.4) | 7(30.4) | χ2=1.075 | 0.300 |
恶性肿瘤家族史[例(%)] | 5(21.7) | 6(26.1) | χ2=0.119 | 0.730 |
腹痛[例(%)] | 12(52.2) | 12(52.2) | χ2=0 | 1 |
发热[例(%)] | 5(21.7) | 2(8.7) | χ2=0.674 | 0.412 |
黄疸[例(%)] | 2(8.7) | 3(13.0) | χ2=0 | 1 |
腹部包块[例(%)] | 1(4.4) | 0(0.0) | 1* | |
体重下降[例(%)] | 8(34.8) | 8(34.8) | χ2=0 | 1 |
纳差[例(%)] | 3(13.0) | 3(13.0) | χ2=0 | 1 |
乏力[例(%)] | 2(8.7) | 3(13.0) | χ2=0 | 1 |
项目 | PTB ( | PMT ( | 统计量 | |
---|---|---|---|---|
WBC(109/L) | 6.19±2.25 | 6.06±2.47 | 0.849 | |
Hb(g/L) | 129.74±15.14 | 129.13±14.72 | 0.891 | |
PLT(109/L) | 223(153, 276) | 206(173, 229) | 0.368 | |
ALT(U/L) | 20(12, 37) | 19(13, 27) | 0.676 | |
AST(U/L) | 23.5(16.25, 31.75) | 21(16.5, 26.5) | 0.834 | |
GGT(U/L) | 27(20.5, 95.5) | 23(14.5, 37) | 0.201 | |
ALP(U/L) | 85.5(75, 140) | 81(66.5, 101) | 0.297 | |
TBIL(μmol/L) | 10.8(7.3, 15.9) | 11.5(7.8, 15) | 1 | |
DBIL(μmol/L) | 3.3(2.5, 5.6) | 3.9(2.9, 5.2) | 0.495 | |
ALB(g/L) | 41.91±4.46 | 40.09±4.54 | t=1.376 | 0.176 |
Scr(μmol/L) | 67.74±10.32 | 66.48±11.45 | t=0.392 | 0.697 |
AMY(U/L) | 106.7±219.25 | 102.21±70.50 | t=0.085 | 0.933 |
LIP(U/L) | 213.83±168.75 | 498.16±686.83 | t=-1.75 | 0.095 |
CRP(mg/L) | 5.09(3.09, 36.89) | 1.62(0.60, 11.09) | 0.031 | |
CEA(ng/ml) | 2.05(1.20, 2.85) | 2.5(1.82, 3.28) | 0.156 | |
CA199(U/L) | 12.25(7.85, 25.80) | 19.90(8.07, 96.88) | 0.559 | |
CA125(U/L) | 14(10.5, 57) | 10.35(7.7, 15.4) | 0.257 |
Tab. 2 Comparison of laboratory examination between groups
项目 | PTB ( | PMT ( | 统计量 | |
---|---|---|---|---|
WBC(109/L) | 6.19±2.25 | 6.06±2.47 | 0.849 | |
Hb(g/L) | 129.74±15.14 | 129.13±14.72 | 0.891 | |
PLT(109/L) | 223(153, 276) | 206(173, 229) | 0.368 | |
ALT(U/L) | 20(12, 37) | 19(13, 27) | 0.676 | |
AST(U/L) | 23.5(16.25, 31.75) | 21(16.5, 26.5) | 0.834 | |
GGT(U/L) | 27(20.5, 95.5) | 23(14.5, 37) | 0.201 | |
ALP(U/L) | 85.5(75, 140) | 81(66.5, 101) | 0.297 | |
TBIL(μmol/L) | 10.8(7.3, 15.9) | 11.5(7.8, 15) | 1 | |
DBIL(μmol/L) | 3.3(2.5, 5.6) | 3.9(2.9, 5.2) | 0.495 | |
ALB(g/L) | 41.91±4.46 | 40.09±4.54 | t=1.376 | 0.176 |
Scr(μmol/L) | 67.74±10.32 | 66.48±11.45 | t=0.392 | 0.697 |
AMY(U/L) | 106.7±219.25 | 102.21±70.50 | t=0.085 | 0.933 |
LIP(U/L) | 213.83±168.75 | 498.16±686.83 | t=-1.75 | 0.095 |
CRP(mg/L) | 5.09(3.09, 36.89) | 1.62(0.60, 11.09) | 0.031 | |
CEA(ng/ml) | 2.05(1.20, 2.85) | 2.5(1.82, 3.28) | 0.156 | |
CA199(U/L) | 12.25(7.85, 25.80) | 19.90(8.07, 96.88) | 0.559 | |
CA125(U/L) | 14(10.5, 57) | 10.35(7.7, 15.4) | 0.257 |
项目 | PTB (n=23) | PMT (n=23) | χ2值 | P值 |
---|---|---|---|---|
超声 | 14 | 14 | ||
病灶部位[例(%)] | ||||
胰头 | 9(64.3) | 5(35.7) | 2.286 | 0.131 |
胰颈 | 0(0.0) | 2(14.3) | 0.481* | |
胰体 | 2(14.3) | 3(21.4) | 0 | 1 |
胰尾 | 3(21.4) | 4(28.6) | 0 | 1 |
回声表现[例(%)] | ||||
囊性 | 2(14.3) | 2(14.3) | 0 | 1 |
实性 | 3(21.4) | 3(21.4) | 0 | 1 |
囊实性 | 5(35.7) | 6(42.9) | 0.15 | 0.699 |
未描述 | 4(28.6) | 3(21.4) | 0 | 1 |
胰周淋巴结肿大[例(%)] | 4(28.6) | 1(7.1) | 0.974 | 0.324 |
CT | 21 | 20 | ||
病灶部位[例(%)] | ||||
胰头 | 12(57.1) | 5(25.0) | 4.361 | 0.037 |
胰颈 | 1(4.8) | 4(20.0) | 1.026 | 0.311 |
胰体 | 4(19.1) | 5(30.0) | 0.666 | 0.414 |
胰尾 | 2(9.5) | 7(35.0) | 2.536 | 0.111 |
病变大小(cm) | 3.7(2.95, 5.55) | 3.4(2.1, 5.5) | 0.223 | 0.825 |
占位表现[例(%)] | ||||
低密度 | 19(90.5) | 16(80.0) | 0.257 | 0.612 |
高密度 | 1(4.8) | 2(10.5) | 0.008 | 0.928 |
密度不均 | 7(33.3) | 2(11.1) | 1.59 | 0.207 |
增强CT[例(%)] | 18 | 18 | ||
无明显强化 | 1(5.6) | 5(27.8) | 1.8 | 0.18 |
环形强化 | 2(11.1) | 1(5.6) | 0 | 1 |
非环形强化 | 15(83.3) | 12(66.7) | 0.593 | 0.441 |
胰周淋巴结肿大[例(%)] | 14(66.7) | 5(25) | 7.152 | 0.007 |
胰管扩张[例(%)] | 0(0) | 10(50) | <0.01* | |
病变部位#[例(%)] | 23 | 23 | ||
胰头 | 12(52.2) | 7(30.4) | 2.242 | 0.134 |
胰颈 | 1(4.3) | 4(17.4) | 0.898 | 0.343 |
胰体 | 5(21.7) | 6(26.1) | 0.119 | 0.73 |
胰尾 | 3(13.0) | 8(34.8) | 2.987 | 0.084 |
胰周淋巴结肿大 | 15(65.2) | 6(30.0) | 5.310 | 0.021 |
Tab. 3 Comparison of imaging performance between groups
项目 | PTB (n=23) | PMT (n=23) | χ2值 | P值 |
---|---|---|---|---|
超声 | 14 | 14 | ||
病灶部位[例(%)] | ||||
胰头 | 9(64.3) | 5(35.7) | 2.286 | 0.131 |
胰颈 | 0(0.0) | 2(14.3) | 0.481* | |
胰体 | 2(14.3) | 3(21.4) | 0 | 1 |
胰尾 | 3(21.4) | 4(28.6) | 0 | 1 |
回声表现[例(%)] | ||||
囊性 | 2(14.3) | 2(14.3) | 0 | 1 |
实性 | 3(21.4) | 3(21.4) | 0 | 1 |
囊实性 | 5(35.7) | 6(42.9) | 0.15 | 0.699 |
未描述 | 4(28.6) | 3(21.4) | 0 | 1 |
胰周淋巴结肿大[例(%)] | 4(28.6) | 1(7.1) | 0.974 | 0.324 |
CT | 21 | 20 | ||
病灶部位[例(%)] | ||||
胰头 | 12(57.1) | 5(25.0) | 4.361 | 0.037 |
胰颈 | 1(4.8) | 4(20.0) | 1.026 | 0.311 |
胰体 | 4(19.1) | 5(30.0) | 0.666 | 0.414 |
胰尾 | 2(9.5) | 7(35.0) | 2.536 | 0.111 |
病变大小(cm) | 3.7(2.95, 5.55) | 3.4(2.1, 5.5) | 0.223 | 0.825 |
占位表现[例(%)] | ||||
低密度 | 19(90.5) | 16(80.0) | 0.257 | 0.612 |
高密度 | 1(4.8) | 2(10.5) | 0.008 | 0.928 |
密度不均 | 7(33.3) | 2(11.1) | 1.59 | 0.207 |
增强CT[例(%)] | 18 | 18 | ||
无明显强化 | 1(5.6) | 5(27.8) | 1.8 | 0.18 |
环形强化 | 2(11.1) | 1(5.6) | 0 | 1 |
非环形强化 | 15(83.3) | 12(66.7) | 0.593 | 0.441 |
胰周淋巴结肿大[例(%)] | 14(66.7) | 5(25) | 7.152 | 0.007 |
胰管扩张[例(%)] | 0(0) | 10(50) | <0.01* | |
病变部位#[例(%)] | 23 | 23 | ||
胰头 | 12(52.2) | 7(30.4) | 2.242 | 0.134 |
胰颈 | 1(4.3) | 4(17.4) | 0.898 | 0.343 |
胰体 | 5(21.7) | 6(26.1) | 0.119 | 0.73 |
胰尾 | 3(13.0) | 8(34.8) | 2.987 | 0.084 |
胰周淋巴结肿大 | 15(65.2) | 6(30.0) | 5.310 | 0.021 |
序号 | 年龄/ 性别 | 组织获取 方式 | 组织病原学 | 免疫学 | 组织病理学 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
抗酸染色 | 分枝杆菌培养 | PCR | PPD | T-SPOT.TB | 上皮样肉芽肿 | 干酪样坏死 | 多核巨细胞 | |||||
1 | 66/女 | 手术 | + | + | / | - | + | + | - | + | ||
2 | 27/男 | 穿刺 | + | + | / | - | + | + | - | + | ||
3 | 45/男 | 穿刺 | - | - | + | + | + | + | - | + | ||
4 | 50/男 | 穿刺 | + | / | / | - | + | + | + | + | ||
5 | 49/女 | 手术 | + | / | / | - | / | + | - | - |
Tab. 4 PTB patients information confirmed through etiological diagnosis
序号 | 年龄/ 性别 | 组织获取 方式 | 组织病原学 | 免疫学 | 组织病理学 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
抗酸染色 | 分枝杆菌培养 | PCR | PPD | T-SPOT.TB | 上皮样肉芽肿 | 干酪样坏死 | 多核巨细胞 | |||||
1 | 66/女 | 手术 | + | + | / | - | + | + | - | + | ||
2 | 27/男 | 穿刺 | + | + | / | - | + | + | - | + | ||
3 | 45/男 | 穿刺 | - | - | + | + | + | + | - | + | ||
4 | 50/男 | 穿刺 | + | / | / | - | + | + | + | + | ||
5 | 49/女 | 手术 | + | / | / | - | / | + | - | - |
[1] | World Health Organization. Grobal tuberculosis report 2022[R]. Geneva: World Health Organization, 2022. |
[2] |
Ray S, Das K, Ghosh R. Isolated pancreatic and peripancreatic nodal tuberculosis: A single-centre experience[J]. Trop Doct, 2021, 51(2):203-209.
doi: 10.1177/0049475520962941 pmid: 33104450 |
[3] |
Tosun S, Tosun A. Imaging of malignancy-suspected pancreatic involvement of extrapulmonary tuberculosis[J]. Turk J Gastroenterol, 2010, 21(1):54-59.
pmid: 20533115 |
[4] |
Auerbach O. Acute generalized miliary tuberculosis[J]. Am J Pathol, 1944, 20(1):121-136.
pmid: 19970738 |
[5] |
Paraf A, Ménager C, Texier J. La tuberculose du pancréas et la tuberculose des ganglions de l'étage supérieur de l'abdomen [Tuberculosis of the pancreas and tuberculosis of the lymph nodes of the upper region of the abdomen][J]. Rev Med Chir Mal Foie, 1966, 41(3):101-126.
pmid: 5944700 |
[6] |
Meesiri S. Pancreatic tuberculosis with acquired immunodeficiency syndrome: A case report and systematic review[J]. World J Gastroenterol, 2012, 18(7):720-726.
doi: 10.3748/wjg.v18.i7.720 URL |
[7] |
Panic N, Maetzel H, Bulajic M, et al. Pancreatic tuberculosis: A systematic review of symptoms, diagnosis and treatment[J]. United European Gastroenterol J, 2020, 8(4):396-402.
doi: 10.1177/2050640620902353 URL |
[8] |
Chaudhary P, Bhadana U, Arora MP. Pancreatic tuberculosis[J]. Indian J Surg, 2015, 77(6):517-524.
doi: 10.1007/s12262-015-1318-4 pmid: 26884661 |
[9] |
Agarwal S, Chaurasia Z, Malik DK, et al. The real burden of tuberculosis: hidden cases diagnosed on autopsy at a tertiary care center of India[J]. Int J Mycobacteriology, 2022, 11(1):47-50.
doi: 10.4103/ijmy.ijmy_227_21 URL |
[10] |
Torres US, Matsumoto C, de Macedo Neto AC, et al. Common and uncommon benign pancreatic lesions mimicking malignancy: Imaging update and review[J]. Semin Ultrasound CT MR, 2018, 39(2):206-219.
doi: S0887-2171(17)30111-7 pmid: 29571556 |
[11] |
Nagar AM, Raut AA, Morani AC, et al. Pancreatic tuberculosis: A clinical and imaging review of 32 cases[J]. J Comput Assist Tomogr, 2009, 33(1):136-141.
doi: 10.1097/RCT.0b013e31816c82bc pmid: 19188801 |
[12] |
Xia F, Poon RT, Wang SG, et al. Tuberculosis of pancreas and peripancreatic lymph nodes in immunocompetent patients: experience from China[J]. World J Gastroenterol, 2003, 9(6):1361-1364.
doi: 10.3748/wjg.v9.i6.1361 URL |
[13] |
Rana SS, Bhasin DK, Srinivasan R, et al. Distinctiveendoscopic ultrasound features of isolated pancreatic tuberculosis andrequirements for biliary stenting[J]. Clin Gastroenterol Hepatol, 2012, 10(3):323-325.
doi: 10.1016/j.cgh.2011.10.018 URL |
[14] |
Santhosh S, Mittal BR, Bhasin D, et al. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics[J]. J Gastroenterol Hepatol, 2013, 28(2):255-261.
doi: 10.1111/jgh.2013.28.issue-2 URL |
[15] |
Shreve PD. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease[J]. Eur J Nucl Med, 1998, 25(3):259-264.
doi: 10.1007/s002590050226 pmid: 9580859 |
[16] |
Song TJ, Lee SS, Park DH, et al. Yield of EUS-guided FNA on the diagnosis of pancreatic/peripancreatic tuberculosis[J]. Gastrointest Endosc, 2009, 69(3 Pt 1):484-491.
doi: 10.1016/j.gie.2008.10.007 pmid: 19231490 |
[17] |
Chang KJ, Nguyen P, Erickson RA, et al. The clinical utility of endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of pancreatic carcinoma[J]. Gastrointest Endosc, 1997, 45(5):387-393.
doi: 10.1016/s0016-5107(97)70149-4 pmid: 9165320 |
[18] |
Varadarajulu S, Wallace MB. Applications of endoscopic ultrasonography in pancreatic cancer[J]. Cancer Control, 2004, 11(1):15-22.
pmid: 14749619 |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||